An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as a
surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Cell-free DNA fragments are shed into the bloodstream by tumor cells. The analysis of
circulating tumor DNA (ctDNA), commonly known as liquid biopsy, can be exploited for a …

Purpose: Up to 30% of patients with breast cancer relapse after primary treatment. There are
no sensitive and reliable tests to monitor these patients and detect distant metastases before …

Breast cancer is the most common cancer among women worldwide. Due to its complexity in
nature, effective breast cancer treatment can encounter many challenges. Traditional …

Background & Aims We aimed to investigate the clinical utility of circulating tumor cell DNA
(ctDNA) and exosome DNA (exoDNA) in pancreatic cancer. Methods We collected liquid …

Most cancer-related deaths are a result of metastasis, and thus the importance of this
process as a target of therapy cannot be understated. By asking 'how can we effectively treat …

Liquid biopsies collect and analyze tumor components in body fluids, and there is an
increasing interest in the investigation of liquid biopsies as a surrogate for tumor tissue in the …

Cancer, a local disease at an early stage, systemically evolves as it progresses by triggering
alterations in surrounding microenvironment, disturbing immune surveillance and further …

Precision Medicine is becoming the new paradigm in healthcare as it enables better
resources allocation, treatment optimization with a potential side-effects reduction and …

In the global context, the epidemic of breast cancer (BC) is evident for the early 21st century.
Evidence shows that national mammography screening programs have sufficiently reduced …